Novo CEO tells CNBC why drugmaker is rebranding, needs to 'rethink' obesity strategyThe Danish drugmaker called the changes the beginning of a new chapter for the company, which faces stiff competition from Eli Lilly.{}

The Danish drugmaker called the changes the beginning of a new chapter for the company, which faces stiff competition from Eli Lilly.https://www.cnbc.com/2026/09/14/novo-nordisk-rebrands-to-novo-ceo-mike-doustdar.html